SLC52A1 and cholangiocarcinoma: Interestingly, C-G2P pinpointed, among others, expression of solute carrier family 15 member 2 (Slc15a2) for which genomic variants have been linked to sorafenib-therapy response29 as well as pancreatic glycoprotein 2 (Gp2) as being associated with CCA (Fig. 5b and Supplementary Fig. 6).